TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34036235
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (CTx) alone
Study: 35077429
Drug: Perforating fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perforating fat injections (2.6 ± 1.6 ml of fat injected per foot at one to two sites)
Study: 35077429
Drug: Perforating fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perforating fat injections
Study: 33378139
Drug: Pretomanid 400
Normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretomanid 400 mg
Study: 33378139
Drug: Pretomanid 1000
Normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretomanid 1000 mg
Study: 33378139
Drug: Pretomanid 400
Normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretomanid 400 mg plus Moxifloxacin 400 mg
Study: 33025342
Drug: Ozanimod (0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (0.23 mg on days 1-4, 0.46 mg on days 5-7, 0.92 mg on days 8-10, and 1.84 mg on days 11-30) + Pseudoephedrine (PSE) 60 mg on day 30
Study: 33025342
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Pseudoephedrine (PSE) 60 mg on day 30
Study: 34244284
Drug: Mechanical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical and oral antibiotic bowel preparation (MOABP)
Study: 34544182
Drug: Lactate-guided therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-guided therapy
Study: 35304275
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Cassia seed powder (0.3 g once daily)
Study: 35304275
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Cassia seed powder (3.0 g once daily)
Study: 37535775
Drug: Ozone injection
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone injection
Study: 35367469
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) at 20 μg/m3
Study: 35367469
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) at 50 μg/m3
Study: 35367469
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) at 150 μg/m3
Study: 36087008
Drug: Batoclimab 680
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batoclimab 680 mg with IVMP
Study: 36087008
Drug: Batoclimab 340
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batoclimab 340 mg with IVMP
Study: 35547000
Drug: Chiglitazar (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar (32 mg)
Study: 35547000
Drug: Chiglitazar (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiglitazar (48 mg)
Study: 33710299
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of the oral GABA reuptake inhibitor tiagabine
Study: 35981820
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy with conservative management
Study: 35981820
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy with invasive management
Study: 32541132
Drug: Hydrogen (H2)
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen (H2) therapy
Study: 32541132
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no H2 therapy)
Study: 32541132
Drug: H2 +
Normalized name: Histamine H2 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 + chemotherapy
Study: 32541132
Drug: H2 +
Normalized name: Histamine H2 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 + targeted therapy
Study: 32541132
Drug: H2 +
Normalized name: Histamine H2 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 + immunotherapy
Study: 32541132
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy groups (H2 with chemotherapy, targeted therapy, or immunotherapy)
Study: 35738852
Drug: Ranolazine treatment
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine treatment
Study: 35738852
Drug: Ranolazine treatment
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine treatment in patients with cardiac resynchronization therapy (CRT) ICDs
Study: 35738852
Drug: Ranolazine treatment
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine treatment in patients with ICDs without CRT
Study: 35738852
Drug: Concomitant AAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant AAD therapy
Study: 33177429
Drug: Various surgical
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various surgical treatments for tibial plateau fractures
Study: 37638083
Drug: Morphine (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (control group)
Study: 33451253
Drug: Eccentric loading
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eccentric loading program followed by stretching exercises combined with extracorporeal shockwave therapy (ESWT)
Study: 32223566
Drug: Ayurvedic multiherbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic multiherbal medication administered daily for 1 month followed by 5 months of oral medication.
Study: 33091863
Drug: Total liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total liver volume (T), left liver volume (L), right liver volume (R), caudate liver volume (C), spleen volume (S), L/T ratio, C/T ratio
Study: 36129886
Drug: Jewelry-making sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jewelry-making sessions held twice a week for four weeks
Study: 32835877
Drug: 5-Aminolevulinic Acid-mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Aminolevulinic Acid-mediated Photodynamic Therapy (5-ALA-PDT)
Study: 33001138
Drug: Hydroxychloroquine, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine, 600 mg daily for 8 weeks
Study: 33969792
Drug: Vancomycin-heparin-lock
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin-heparin-lock
Study: 33969792
Drug: Non-heparin, high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin, high-dose vancomycin-lock
Study: 32729820
Drug: JY09 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: JY09 6.0 mg
Study: 32729820
Drug: JY09 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: JY09 (various doses 0.3, 0.7, 1.5, 3.0, and 6.0 mg)
Study: 34171938
Drug: AS201‐01 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS201‐01 tablets (4 tablets, twice daily for 4 days)
Study: 34171938
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (4 tablets, twice daily for 4 days)
Study: 32623839
Drug: metformin 1,000‐1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 1,000‐1,500 mg daily
Study: 35501887
Drug: Trained community‐oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained community‐oriented resource persons (CORPs) conducting community‐based screening of BP, referral, diagnosis confirmation, initial treatment, monthly home‐based follow-up care, and health education.
Study: 35501887
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (diagnosis, treatment and follow‐up care in hospital of a patient’s choice).
Study: 33958325
Drug: Tight-control/treat-to-target strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight-control/treat-to-target strategy (TC/T2T) with visits every 4 weeks and treatment intensification until achieving ASDAS <2.1
Study: 33958325
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) with visits every 12 weeks and treatment at the rheumatologist's discretion
Study: 34521465
Drug: MED intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MED intervention (medication review by a pharmacist and geriatrician in the ED)
Study: 35137699
Drug: Antipsychotics (off-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotics (off-label use)
Study: 35137699
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antipsychotics after 4 months
Study: 33567589
Drug: Water Replenishment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Replenishment Group 1 (1000 mL)
Study: 33567589
Drug: Water Replenishment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Replenishment Group 2 (500 mL)
Study: 33567589
Drug: Water Replenishment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Replenishment Group 3 (200 mL)
Study: 36076107
Drug: Inhaled vanilla
Normalized name: Vanilla
DrugBank: Vanilla (DB10576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled vanilla essential oil (VEO)
Study: 35377106
Drug: Inhaled lavender
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled lavender essential oil (LEO)
Study: 35938913
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase before endovascular treatment
Study: 35938913
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment only
Study: 32539893
Drug: CS200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS200 (200 mg CS per kg feed)
Study: 32539893
Drug: CS100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS100 (100 mg CS per kg feed)
Study: 35014145
Drug: Triple Therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Therapy (metformin/exenatide/pioglitazone)
Study: 35014145
Drug: Conventional Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Therapy (metformin → glipizide → glargine insulin)
Study: 35014145
Drug: Triple Therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Therapy
Study: 32394855
Drug: Selexipag (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (doses: 1200‐1600 µg b.i.d., 600‐1000 µg b.i.d., 200‐400 µg b.i.d.)
Study: 35251561
Drug: EPOC training
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOC training in addition to conventional medication
Study: 35251561
Drug: Conventional hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hypertension medication
Study: 34034929
Drug: CNS-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS-directed therapy comprising four to 11 courses of i.v. methotrexate (5 g/m2) and 10 to 19 intrathecal chemotherapy injections, depending on risk group and CNS status.
Study: 32020813
Drug: Pre-bronchodilator spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-bronchodilator spirometry
Study: 32020813
Drug: Post-bronchodilator spirometry
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator spirometry
Study: 32020813
Drug: Treatment status
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment status
Study: 36435746
Drug: Providers with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Providers with a reduction in antibiotic prescribing
Study: 32224082
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) 1 g intravenously preoperatively
Study: 35130054
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g acetaminophen 4× daily
Study: 34971331
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation of the rectus femoris and gastrocnemius muscles bilaterally, applied for 60 min, twice a day for up to 10 sessions until postoperative day 5.
Study: 38283689
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine
Study: 36951156
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine maintenance therapy
Study: 34751784
Drug: Hip-focused treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip-focused treatment
Study: 34751784
Drug: Spine-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spine-focused treatment
Study: 35182115
Drug: Treatment and
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment and prevention complex
Study: 33350370
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg single dose)
Study: 34514614
Drug: Remifentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil plasma target concentration of 0 ng/ml (group R0)
Study: 34514614
Drug: Remifentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil plasma target concentration of 1 ng/ml (group R1)
Study: 34514614
Drug: Remifentanil plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil plasma target concentration of 2 ng/ml (group R2)
Study: 36194619
Drug: Oral Qurs‐e‐Asfar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Qurs‐e‐Asfar (QA) 778 mg twice a day and topical Rogan‐e‐Narjeel (RN)
Study: 36194619
Drug: Oral Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Itraconazole (100 mg/day) and topical Terbinafine hydrochloride (1%)
Study: 34710784
Drug: Sildenafil tablets
Normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil tablets
Study: 33509742
Drug: Curcumin mucoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin mucoadhesive patches
Study: 34789394
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m2 every 3 wk × 4 cycles)
Study: 34789394
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 every 3 wk × 4 cycles)
Study: 35098012
Drug: Infertility treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infertility treatment training program (Control)
Study: 35617841
Drug: Twice-daily hypertonic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily hypertonic saline irrigation for 6 weeks
Study: 35617841
Drug: Twice-daily saline/xylitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily saline/xylitol irrigation for 6 weeks
Study: 34516169
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (target BAC = .08%)
Study: 32838679
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First with Assertive Community Treatment (ACT)
Study: 33705169
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (DESTRESS-WV and phone monitoring)
Study: 36268543
Drug: Internet-based writing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based writing intervention (6 weeks, six structured writing assignments based on cognitive behavioral therapy)
Study: 34825283
Drug: Preoperative prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative prophylactic antibiotics
Study: 34825283
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no preoperative prophylactic antibiotics)
Study: 32862425
Drug: Supervised group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group exercise (12 weeks, twice weekly)
Study: 36808268
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg ODT
Study: 36891452
Drug: PECs II
Approvals — FDA: no, EMA: no, PMDA: no
Description: PECs II block with 25 ml of 0.25% bupivacaine
Study: 34288696
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of FOLFIRINOX followed by leucovorin plus fluorouracil maintenance treatment (arm B)
Study: 34288696
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment alternating gemcitabine and fluorouracil, leucovorin, and irinotecan every 2 months (arm C)
Study: 35076797
Drug: PrEP taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP taken by daily pill
Study: 35076797
Drug: PrEP by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP by injection
Study: 35076797
Drug: PrEP by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP by pill
Study: 35076797
Drug: Other PrEP
Normalized name: other preparations, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other PrEP modalities (event-based pill, anal suppository, gel, condoms)
Study: 32246765
Drug: GM-CSF (intrauterine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (intrauterine infusion)
Study: 32246765
Drug: Control (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (gel without GM-CSF)
Study: 32827307
Drug: Prophylactic nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic nimodipine treatment
Study: 34563097
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant epidermal growth factor (h‐EGF) in 2% carboxymethyl cellulose gel
Study: 34563097
Drug: 2% carboxymethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% carboxymethyl cellulose gel (control)
Study: 34654942
Drug: GI-0.025 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: GI-0.025 mL
Study: 34654942
Drug: GII-0.05 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: GII-0.05 mL
Study: 34654942
Drug: GIII-0.10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIII-0.10 mL
Study: 32243582
Drug: Paroxetine (5-HT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (5-HT reuptake inhibitor)
Study: 2011535125
Drug: Pedimed cream
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedimed cream
Study: 34735098
Drug: Bupropion (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150-300 mg/d)
Study: 32573927
Drug: Exenatide ER
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide ER 2 mcg weekly
Study: 35490395
Drug: Baricitinib (BARI)
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib (BARI) 2-4 mg
Study: 35490395
Drug: Baricitinib (BARI)
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib (BARI) 2 mg
Study: 35490395
Drug: Baricitinib (BARI)
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib (BARI) 4 mg
Study: 34118259
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with morphine 1 mcg.kg-1 (n=15)
Study: 35977762
Drug: Oral pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pills
Study: 34214736
Drug: Fractionated HPC
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated HPC infusion (4 × 10^6 CD34+ cells/kg on day 0, remaining cells infused on days 2, 4, and 6)
Study: 34214736
Drug: Bulk HPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk HPC infusion (7 × 10^6 CD34+ cells/kg)
Study: 34214736
Drug: Fractionated HPC
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated HPC infusion
Study: 34214736
Drug: Bulk HPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk HPC infusion
Study: 35135986
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 800 mg daily
Study: 35642697
Drug: Core stability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core stability exercise program (30 min, in addition to standard physical therapy program)
Study: 35642697
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy program (1 h per session, three times weekly)
Study: 35935235
Drug: LTBI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTBI treatment (specific regimen not detailed)
Study: 35549538
Drug: Escitalopram (8-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (8-week treatment)
Study: 34980541
Drug: Chemotherapy (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (arm A)
Study: 36008895
Drug: Allopurinol orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol orally, 100 mg/time, tid, for 12 weeks
Study: 35339323
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) with traditional rehabilitation
Study: 36229155
Drug: Healthy Habits
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Habits Triple P - Oral health (web-based parenting intervention)
Study: 36229155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral health-related information published by Australian oral health agencies)
Study: 32228315
Drug: Pazopanib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (600 mg orally daily in 2 divided doses, 400 and 200 mg) and cyclophosphamide (50 mg orally daily for 21 days every 28 days)